Cargando…

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (CAP) and tegafur. Bioconversion of 5-FU prodrugs to 5-FU and subsequent metabolic activation of 5-FU are requ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maslarinou, Anthi, Manolopoulos, Vangelis G., Ragia, Georgia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226670/ https://www.ncbi.nlm.nih.gov/pubmed/37256234 http://dx.doi.org/10.3389/fphar.2023.1184523

Ejemplares similares

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
por: Lau, David K., et al.
Publicado: (2023)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review
por: Atzemian, Natalia, et al.
Publicado: (2023)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
por: García-Alfonso, P., et al.
Publicado: (2021)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
por: da Rocha, Jorge E. B., et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2 mediated SARS-CoV-2 entry
por: Ragia, Georgia, et al.
Publicado: (2020)

Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
por: Ragia, Georgia, et al.
Publicado: (2020)

Beyond the Rhythm: In Silico Identification of Key Genes and Therapeutic Targets in Atrial Fibrillation
por: Atzemian, Natalia, et al.
Publicado: (2023)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Pharmacogenomics in practice: a review and implementation guide
por: Kabbani, Danya, et al.
Publicado: (2023)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia
por: Alzahrani, Abdullah M., et al.
Publicado: (2013)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Association of Functional VKORC1 Promoter Polymorphism with Occurrence and Clinical Aspects of Ischemic Stroke in a Greek Population
por: Ragia, Georgia, et al.
Publicado: (2013)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Pharmacogenomics: What is Next?
por: di Iulio, Julia, et al.
Publicado: (2012)

Pharmacogenomics in oncology care
por: Filipski, Kelly K., et al.
Publicado: (2014)

Editorial: NSAIDs Pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2021)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis
por: Lu, Yajie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15jhnt4il4igli7i3s4i30qkrr